DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: * DC/MM fusion vaccine (a type of personalized cancer vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)

Trial Details

NCT ID
NCT07377435
Phase
PHASE1
Sponsor
David Avigan
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • DC/MM Fusion Vaccine
  • GM-CSF
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Patients must be eligible to receive standard of care CAR T-cell therapy for relapsed or refractory multiple myeloma
  • Patients must be ≥18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Patients must have 20% or more plasma cells in the bone marrow core or aspirate differential within 30 days prior to enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →